Patents by Inventor Eliav Barr

Eliav Barr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6436907
    Abstract: The present invention relates to the use of adenovirus-mediated gene transfer to regulate function in cardiac and vascular smooth muscle cells. A recombinant adenovirus comprising a DNA sequence that codes for a gene product is delivered to a cardiac or vascular smooth muscle cell and the cell is maintained until that gene product is expressed. Delivery is direct injection into a muscle cell or infusing a pharmaceutical composition containing an adenovirus virus vector construct intravascularly.
    Type: Grant
    Filed: November 5, 1998
    Date of Patent: August 20, 2002
    Assignee: Arch Development Corporation
    Inventors: Jeffrey M. Leiden, Eliav Barr
  • Publication number: 20020077311
    Abstract: A novel method for expressing a protein which comprises: transforming skeletal myoblasts or cardiac myocytes with a DNA sequence comprising a DNA segment encoding a selected gene downstream of the Rous sarcoma virus long terminal repeat or the expression sequence in pRSV, and implanting said skeletal myoblasts or cardiac myocytes into a recipient which then expresses a physiologically effective level of said protein.
    Type: Application
    Filed: September 13, 2001
    Publication date: June 20, 2002
    Applicant: The Regents of The University of Michigan
    Inventors: Jeffrey Leiden, Eliav Barr
  • Patent number: 6316419
    Abstract: A novel method for expressing a protein which comprises: transforming skeletal myoblasts or cardiac myocytes with a DNA sequence comprising a DNA segment encoding a selected gene downstream of the Rous sarcoma virus long terminal repeat or the expression sequence in pRSV, and implanting said skeletal myoblasts or cardiac Myocytes into a recipient which then expresses a physiologically effective level of said protein.
    Type: Grant
    Filed: August 12, 1997
    Date of Patent: November 13, 2001
    Assignee: University of Michigan
    Inventors: Jeffrey M. Leiden, Eliav Barr
  • Patent number: 6297220
    Abstract: The present invention relates to the use of adenovirus-mediated gene transfer to regulate function in cardiac and vascular smooth muscle cells. A recombinant adenovirus comprising a DNA sequence that codes for a gene product is delivered to a cardiac or vascular smooth muscle cell and the cell is maintained until that gene product is expressed. Delivery is direct injection into a muscle cell or infusing a pharmaceutical composition containing an adenovirus virus vector construct intravascularly.
    Type: Grant
    Filed: November 18, 1997
    Date of Patent: October 2, 2001
    Assignee: Arch Development Corporation
    Inventors: Jeffrey M. Leiden, Eliav Barr